Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer-Reference-Cited by-同舟云学术

Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer

Published:2007-05-22 Issue:3 Volume:24 Page:301-307
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Makatsoris Thomas,Papakostas Pavlos,Kalofonos Haralabos P.,Xanthakis Ioannis,Tsavdaridis Dimitrios,Aravantinos Gerasimos,Gogas Helen,Klouvas George,Kosmidis Paris,Pectasides Dimitrios,Fountzilas George

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-007-0004-1.pdf

Reference25 articles.

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9.

2. Akoh AJ, McIntyre IMC. Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293–9.

3. Wagner AD, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903–9.

4. Cullinan SA, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985;253:2061–7.

5. Wils J. The treatment of advanced gastric cancer. Semin in Oncol 1996;23:397–406.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2016-06

2. Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis;PLoS ONE;2013-04-04

3. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors;Expert Review of Anticancer Therapy;2011-08